SPP1 and atherosclerosis: Because of this, they can be an important biomarker of the response to treatment for atherosclerosis (such as using proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors), especially since studies show that the use of statins leads to a significant decrease in MMPs, OPN, and OPG plasma concentration [24,25].